Kristen Riemenschneider is Counsel in the Intellectual Property and Government Contracts practice groups, focusing on the broad range of legal issues facing technology, biotechnology and pharmaceutical companies, including federal government contractors. Ms. Riemenschneider is a registered patent attorney.
Her experience includes:
- assisting clients in developing global patent strategies and prosecuting utility and design patents in the software, electrical, and mechanical arts;
- drafting agreements for the commercialization of intellectual property and technology, including licensing, collaboration and product development arrangements, service and development contracts, and federal subcontracts; and
- matters arising in connection with the intellectual property regime associated with federal government contracting, such as the role of data rights in federal procurements and the Bayh-Dole Act.
Ms. Riemenschneider joined Arnold & Porter following her clerkship for the Honorable Francis M. Allegra at the United States Court of Federal Claims. She is a graduate of the University of Virginia School of Law, where she served as a Managing Editor of the Virginia Journal of International Law and as an Editor of the Virginia Journal of Law and Technology.
Prior to attending law school, Ms. Riemenschneider worked as an electrical engineer, researching and developing novel biometric authentication and personal security technologies. Ms. Riemenschneider has significant experience with hardware and software development.
Intellectual Property Representative Matters
- OPKO Health, in a license and development agreement with Pfizer for a long-acting human growth hormone (hGH-CTP) for adults and children. The deal terms included a US$295 million upfront payment, an additional US$270 million in milestones, and royalties and a profit share
- A privately-funded charitable foundation in connection with the establishment of a research institute at a private university
- Bayer Consumer Care, in the sale of rights to ATX-101 to Kythera Biopharmaceuticals
- Auven Therapeutics, with an in-license agreement with Five Prime Therapeutics
- Spirogen, in its sale to MedImmune, for US$200 million in cash and deferred consideration of up to US$240 million
- ADC Therapeutics, in a collaboration agreement with MedImmune for two of ADC Therapeutics' antibody drug conjugate programs
- Sequella, in connection with a license and development agreement relating to its tuberculosis product to Maxwell Biotech for development and sale in Russia
- A global pharmaceutical company, in connection with the structuring and negotiation of numerous agreements with research institutions around the world
- A major US company, with the establishment of an endowment to be administered by the US Government.
- Various major pharmaceutical and technology companies, with respect to the Bayh-Dole Act, Cooperative Research and Development Agreements (CRADAs), and waivers of the "substantial US manufacturing" requirement for technology developed with US Government funds
- A foreign technology company, with patent portfolio development and strategy in cryptography and related computer security subject matters
- Various US Government contractors, in data rights disputes with various US Government agencies, including the US Army, US Navy and Defense Threat Reduction Agency